Cholinesterase inhibitors and anticholinergic drugs: is the pharmacologic antagonism myth or reality?
Beier
Manju T
MT
Geriatric Consultant Resources, LLC, Ann Arbor, MI, USA. beier@gcrweb.com <beier@gcrweb.com>
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000187:drug effects*; D001921:Brain / Q000187:drug effects*; D016022:Case-Control Studies; D018680:Cholinergic Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D003072:Cognition Disorders / Q000139:chemically induced / Q000453:epidemiology; D003693:Delirium / Q000139:chemically induced / Q000453:epidemiology; D003704:Dementia / Q000139:chemically induced / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D015577:Geriatric Assessment; D006801:Humans; D015994:Incidence; D008297:Male; D012016:Reference Values; D012189:Retrospective Studies; D018570:Risk Assessment; D012680:Sensitivity and Specificity
D018680:Cholinergic Antagonists; D002800:Cholinesterase Inhibitors